Jon C. Jones - Concepedia

Author

Jon C. Jones

Amgen (United States)ORCID

Also Known As

J Jones, Jon C Jones, Jon C. Jones, Jon Jones

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Amgen (United States)Fred Hutch Cancer Center University of Washington Eureka Therapeutics (United States)Memorial Sloan Kettering Cancer Center

About

Jon C. Jones is an author at Amgen (United States) specializing in medicine, tumor biology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	873
2	Cell Biology	5	5	767
3	Immunology	3	3	114
4	Health Sciences	1	1	53
5	Cellular Therapies	1	1	53

Jon C. Jones

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis Eva González‐Suárez, Allison P. Jacob, Jon C. Jones, Nature Tumor BiologyMammary GlandBreast CancerRank LigandMedicine	2010	583
A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, <i>mdr1a</i>, Spontaneously Develop Colitis C Panwala, Jon C. Jones, Joanne L. Viney The Journal of Immunology	1998	567
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells Eric L. Smith, Kim Harrington, Reed Masakayan, Science Translational Medicine	2019	373
RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes Allison Armstrong, Robert E. Miller, Jon C. Jones, The Prostate	2007	177
Imaging CAR T cell therapy with PSMA-targeted positron emission tomography Il Minn, David Huss, Hye-Hyun Ahn, Science Advances	2019	132
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide Melissa Works, Neha Soni, Collin Hauskins, Molecular Cancer Therapeutics	2019	83
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis Robert E. Miller, Martine P. Roudier, Jon C. Jones, Molecular Cancer Therapeutics	2008	81
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib Jim Qin, Timothy G. Johnstone, Alex Baturevych, Journal of Immunotherapy	2020	75
Quantitative single‐particle digital autoradiography with <i>α</i>‐particle emitters for targeted radionuclide therapy using the iQID camera Brian W. Miller, Sofia H.L. Frost, Shani L. Frayo, Medical Physics	2015	71
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model Damian J. Green, Mazyar Shadman, Jon C. Jones, Blood	2015	63

Page 1